NFKB1 and psoriasis: Liu et al. (Liu et al., 2020) reported that CIM could mitigate imiquimod-induced psoriasis in mice by inhibiting oxidative stress, inhibiting inflammation and repressing NF-κB and MAPK signaling in HaCaT cells.